EUVIMEDEUVIMED entdecken
Crossref

Statin Use During Concurrent Chemoradiotherapy for Advanced Nasopharyngeal Cancer

Jung-Min Yu, Chia-Lun Chang, Kuan-Chou Lin, Wan-Ming Chen, Ben-Chang Shia, Szu-Yuan Wu

Journal of the National Comprehensive Cancer Network · 2024

DOI: 10.6004/jnccn.2024.7046 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2024. Verfasst von Jung-Min Yu und 5 weiteren Autor:innen. Beteiligte Einrichtung: 1Department of Cardiovascular Surgery, Taichung Tzu Chi Hospital, Taichung, Taiwan. Hauptthemen laut MEDLINE: Chemoradiotherapy, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Nasopharyngeal Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The objective of this study was to assess the impact of statin use on overall survival (OS) and nasopharyngeal cancer (NPC)–specific survival in patients with advanced NPC who underwent standard concurrent chemoradiotherapy (CCRT). Patients and Methods: This propensity score matched cohort study used data from the Taiwan Cancer Registry Database and National Health Insurance Research Database to examine the impact of statin use during CCRT on both OS and NPC-specific survival.

Results

Statin use during CCRT demonstrated significant and independent prognostic value for both OS and NPC-specific survival. The adjusted hazard ratio for all-cause mortality in the statin group compared with the nonstatin group was 0.48 (95% CI, 0.34–0.68; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ChemoradiotherapyHydroxymethylglutaryl-CoA Reductase InhibitorsNasopharyngeal NeoplasmsHumansFemaleMaleMiddle AgedAgedAdultTaiwanNeoplasm StagingTreatment OutcomePrognosisPropensity ScoreNasopharyngeal Carcinoma

Substanzen

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • 1Department of Cardiovascular Surgery, Taichung Tzu Chi Hospital, Taichung, Taiwan.
  • 2Department of Surgery, School of Medicine, Tzu Chi University, Hualien, Taiwan.
  • 3Department of Hemato-Oncology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
  • 4Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
  • 5Division of Oral and Maxillofacial Surgery, Department of Dentistry, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
  • 6School of Dentistry, College of Oral Medicine, Taipei Medical University, Taipei, Taiwan.

Zitieren

APA

Yu, J. M., Chang, C. L., Lin, K. C., Chen, W. M., Shia, B. C., & Wu, S. Y. (2024). Statin Use During Concurrent Chemoradiotherapy for Advanced Nasopharyngeal Cancer. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2024.7046

Vancouver

Yu JM, Chang CL, Lin KC, Chen WM, Shia BC, Wu SY. Statin Use During Concurrent Chemoradiotherapy for Advanced Nasopharyngeal Cancer. Journal of the National Comprehensive Cancer Network. 2024. doi:10.6004/jnccn.2024.7046

BibTeX
@article{Yu2024,
  author = {Yu, Jung-Min and Chang, Chia-Lun and Lin, Kuan-Chou and Chen, Wan-Ming and Shia, Ben-Chang and Wu, Szu-Yuan},
  title = {Statin Use During Concurrent Chemoradiotherapy for Advanced Nasopharyngeal Cancer},
  journal = {Journal of the National Comprehensive Cancer Network},
  year = {2024},
  doi = {10.6004/jnccn.2024.7046}
}
Kostenlos starten →